STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA)

WuXi STA

http://www.pharmtech.com/pt_w/pre_formulation

	The development cost and timeline for a new drug is increasing due to high attrition rates caused by inadequate physicochemical and biopharmaceutical attributes, unacceptable safety, and sub-marginal efficacy. This development attrition rate can be reduced by strengthening efficacy and toxicity screens and establishing a developability screen to enable selection of developable compounds to move to the clinic. It is critical to select right formulation principles for efficacy and toxicity screens, and equally important to run developability screens by:

		Physicochemical characterization of new chemical entities

		Integrated pharmacokinetic testing and profiling

		Drug delivery technologies to enable oral bioavailability of poorly water-soluble compounds

			Learn how to select the most developable drug candidate for development

			Learn how to quickly develop Phase 1 formulation

			Learn how to apply drug delivery technologies for enhancing the oral bioavailability of poorly water-soluble molecules

Liang Mao, Director, Developability and Formulation Research, WuXi STA

	Andrew Phimister, CMC Consultant, WuXi STA

Wednesday, Apr. 15, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

	On demand available after airing until Apr. 15, 2021

Webcasts

Looking for a fast pathway to an investigational new drug application (IND) for your new drug candidates? This webcast will discuss strategies to select the most developable molecules and quickly develop an IND-ready formulation within 8–12 weeks using real-world case studies. 
Live: Wednesday, April 15, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Apr. 15, 2021
Register free



WuXi STA

Articles